Browse treatments

…0-mutant melanoma as first-line therapy or after progression on anti-PD-1 therapy. However, prior treatment with BRAF-directed therapy can dimini…

…CC model in immunocompetent mice, either alone or combined with anti-PD-1 therapy.Results Peri-necrotic tumor regions were characterized by hypox…

…ive analysis of samples from 111 melanoma patients treated with anti-PD-1 therapy to quantify PD-1/PD-L1 interactions and to assess their associa…

…ng A3A. In contrast, A3B expression sensitized BBN963 tumors to anti-PD-1 therapy. Furthermore, we have validated in multiple human datasets that…

…bited higher CD8+ T cell infiltration and improved responses to anti-PD-1 therapy.Conclusions Our findings establish a PDO-T cell platform for pr…

…in 1 (PD-1)+T cells accumulation. Furthermore, combination with anti-PD-1 therapy synergistically suppressed tumor growth beyond monotherapy effi…

…d CD8 + T-cell effector function. UXS1 knockout synergized with anti-PD-1 therapy, and in human HCC, high UXS1 correlated with low KMT2D, high PD…

…tial was further evaluated in immunocompetent mice treated with anti-PD-1 therapy.Results We identified ATF4 as a tumor-intrinsic driver of immun…

…1 effectively suppressed tumour progression and synergised with anti-PD-1 therapy, leading to prolonged survival.Conclusion The JOSD1-AARS1 axis …

… PAR-2 negative allosteric modulator I-117, in combination with anti-PD-1 therapy. To further characterize immune changes associated with PAR-2 t…

… Treg expansion and markedly enhanced the antitumor efficacy of anti-PD-1 therapy in murine PM models.Conclusions Our findings identify HA–CD44 s…

…bial alterations to simulate human susceptibility to irAEs upon anti-PD-1 therapy. 3 4 This model faithfully recapitulates human disease in tissu…